Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. - Wikidata - awgldk - TriplyDB

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

http://www.wikidata.org/entity/Q46535501

about

michGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adults Granulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adults High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults Interferon-alpha for maintenance of follicular lymphoma Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901 Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.Hematopoietic stem cell transplantation for the management of follicular lymphoma Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.Role of hematopoietic stem cell transplant in the management of follicular lymphoma.Autologous transplant of follicular lymphoma in the era of rituximab.Expanded use of rituximab in the management of non-Hodgkin lymphoma.Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.Transplantation for non-Hodgkin lymphoma.Hematopoietic cell transplantation for lymphomas.Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Follicular lymphoma: current management and future directions.Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?Current and future management of follicular lymphoma.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).How we manage follicular lymphoma.Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.Autologous hematopoietic cell transplantation: an update for clinicians.Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.Life expectancy of young adults with follicular lymphoma.Update on the role of autologous hematopoietic stem cell transplantation in follicular lymphoma Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.Incidence, risk factors and outcome of histological transformation in follicular lymphoma.

P2860

Q24186266-A4E6A010-02CC-47F8-AFB3-34FF697EBB60 Q24200850-7600F811-21E8-43E6-BAEA-AD303864E850 Q24203878-6FC447A7-8DF3-466E-8FAC-83E0FC8D67A4 Q24240781-357FEF12-A08A-4E41-AE8E-3D87F06555AD Q28066710-9372E291-23D3-48B2-AFDA-B65C2F8760A2 Q28072397-A44AB5C1-A601-4262-8AC9-60AD53E84CE7 Q30248407-BDD18AF4-C090-47E1-8E55-9CD34C8FC8C7 Q33664022-71FD61AF-E1BC-42EC-899A-40CA84520D10 Q35100217-DFB9C6D1-0CB8-46E2-9023-763D3CB29786 Q35143466-B83AD97C-76B5-4DC2-A59B-A855FBCCAAA2 Q36264884-40EAE419-38DC-428A-A52F-E227DFE0468F Q36336614-4A3E3F66-41AB-41EE-9309-4FCD908629D0 Q36862529-6E6B4390-CE3C-43BB-A83F-672DD1C926DC Q36967098-27E1593C-E5EA-4A48-A167-ADBA078084D4 Q36967144-5E4EA931-24B9-4624-B8E4-3185D73F0C37 Q37132248-A9223B90-E6E0-45B6-B4B3-768787F71B29 Q37194061-18BC8EF8-4425-462A-BD51-09261C9CC364 Q37356389-C88799F9-BD62-4FC9-9309-1C1CFE2E1EAC Q37533977-55F32D55-1A3C-41DD-AD5A-1E0B9B03582E Q37742624-07D8369D-58D2-483F-994F-ABC59EE79A34 Q37771248-3A189320-A48F-4CC5-BE65-D5F623EAAB5C Q37773249-592A3E99-D0D5-4FEA-9E46-1314A7A5C362 Q37810079-59A8D4D8-2A7B-4089-87C7-065CDA9C9848 Q37942817-0934A026-D446-427B-B4FD-5259D119C356 Q37948748-2821532C-2FE0-45FA-A4FC-98A99B087DD2 Q38019789-424D3F91-9AB1-4445-A59E-163EA891FA7E Q38045706-630D3B05-0B70-4A79-A0F9-D72C1F3ABDB0 Q38056393-EE15B437-DA17-44CC-83C7-A84F5E0AD852 Q38061883-518BDC02-BA45-425B-A20E-B4A5387C828F Q38191811-2C0C469F-8250-47E5-A1DB-AFBF1195F457 Q38209433-D6F28BEC-058E-436C-AA5E-D3C9D1CC7DA4 Q38248359-C74909F8-6324-49C2-801A-A0531472DC46 Q39685859-A07A9969-19B8-4088-999D-A2F345561711 Q40015002-D91F79AD-748F-4637-8CE4-D0464261B661 Q41370330-A17DE0B7-C700-4921-AB83-F97C74F6BF60 Q42142703-EEF0F011-F545-456A-ADE0-C2E122E63C1F Q43135381-8EBE2CC1-1B20-4686-A873-D25A1CA65A19 Q44736591-EC04776E-C663-4636-8985-A317D3F52DFE Q44908024-56277DBF-B685-4217-8EEB-53FA2D105781 Q45286370-9F8D099C-6F19-4CF6-8FE0-3B0E355F6E79

P2860

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

http://www.wikidata.org/entity/Q46535501

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.

@en

Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.

@nl

type

label

Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.

@en

Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.

@nl

prefLabel

Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.

@en

Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.

@nl

P1433

Q46535501-68CCAA68-BD22-4002-9C88-7A6092751F73

P1476

Q46535501-BB15538D-7A1C-45F9-BB7C-4B87DA50E7A9

P2093

Q46535501-18AFD0B9-D568-4273-A795-26BE29A1E433

Q46535501-3D8FA180-8445-4C6A-A236-6C63E62F1EE9

Q46535501-51FCE441-84B0-409F-B267-5B990A5B5884

Q46535501-8C53A0DE-5BD4-4BAA-8934-FF61B734D312

Q46535501-8F0D2244-9FFF-4A65-BD15-18E2B1EF4213

Q46535501-AB143A97-F908-438B-93E1-8CAA4AB37003

Q46535501-B1E0526E-CBBB-4CB3-8103-812C0700FB39

Q46535501-B5CCC662-09B5-42CB-80A1-BB58E8FB2BE0

Q46535501-ED233EB2-C9CF-4FFF-8535-44D2D8CF14A7

P304

Q46535501-801D4839-9166-4CF7-AC2A-8C1116254F46

P31

Q46535501-ACCB80B7-6AA1-4398-AEFA-6645A1E7C057

P356

Q46535501-55FB6561-2BDC-497E-AB59-751742DF338D

P407

Q46535501-C89703FD-22FC-4ADB-B27F-1EAF9E2853C9

P433

Q46535501-121A7D65-2AD0-4AF8-95D4-90074865B250

P478

Q46535501-6A8B5E2C-E74F-47E4-A046-0F5D301BACCE

P50

Q46535501-23AA6366-0507-4093-A1A1-22687C747588

Q46535501-B41DA875-69EB-4FC6-8653-1A9A59E48396

P577

Q46535501-47B09368-31AA-4B87-8B47-0F43699949CC

P698

Q46535501-F9B38C9A-9EB2-454C-82A7-C215FCF6A4AF

P921

Q46535501-219AE70C-5B7F-4A42-85A6-84D7E2A6C5C1

Q46535501-91C8E13F-A552-42E0-8B8C-4D73AA63EF42

P356

JCO.2007.15.5358

P1433

Journal of Clinical Oncology

P1476

Impact of rituximab and/or hig ...... licular lymphoma: a GELA study

@en

P2093

Bertrand Coiffier

http://www.w3.org/2001/XMLSchema#string

Bertrand Souleau

http://www.w3.org/2001/XMLSchema#string

Catherine Sebban

http://www.w3.org/2001/XMLSchema#string

Hervé Tilly

http://www.w3.org/2001/XMLSchema#string

Nicole Brousse

http://www.w3.org/2001/XMLSchema#string

Pauline Brice

http://www.w3.org/2001/XMLSchema#string

Philippe Solal-Céligny

http://www.w3.org/2001/XMLSchema#string

Pierre Feugier

http://www.w3.org/2001/XMLSchema#string

Richard Delarue

http://www.w3.org/2001/XMLSchema#string

P304

3614-3620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.15.5358

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Mounier

P577

2008-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18559872

http://www.w3.org/2001/XMLSchema#string

P921

autotransplantation